NASDAQ:MRKRTapImmune Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding TapImmune Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.27 -0.20 (-8.10 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$2.19Now: $2.27▼$2.5650-Day Range$1.72MA: $2.26▼$2.7952-Week Range$1.33Now: $2.27▼$9.17Volume844,399 shsAverage Volume609,874 shsMarket Capitalization$105.62 millionP/E RatioN/ADividend YieldN/ABeta0.64 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSocial Media Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is developing TPIV100/110, which is in Phase II clinical trial to treat human epidermal growth factor receptor 2 breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. It is also developing a proprietary nucleic acid-based antigen expression technology, PolyStart, to improve the ability of the immune system to recognize and destroy diseased cells. The company is headquartered in Houston, Texas.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingTapImmune has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.90, TapImmune has a potential upside of 292.1% from its current price of $2.27.Amount of Analyst CoverageTapImmune has only been the subject of 2 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesTapImmune has received 57 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTapImmune has received 64 “underperform” votes. (Add your “underperform” vote.)Community SentimentTapImmune has received 52.89% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about TapImmune and other stocks. Vote “Outperform” if you believe MRKR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MRKR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTapImmune does not currently pay a dividend.Dividend GrowthTapImmune does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TapImmune insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 30.90% of the stock of TapImmune is held by insiders.Percentage Held by InstitutionsOnly 32.07% of the stock of TapImmune is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for TapImmune are expected to decrease in the coming year, from ($0.58) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TapImmune is -4.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TapImmune is -4.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTapImmune has a P/B Ratio of 2.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.16 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRKR Previous Symbol CUSIPN/A CIKN/A Webwww.markertherapeutics.com Phone713-400-6400Debt Debt-to-Equity Ratio0.01 Current Ratio13.27 Quick Ratio13.27Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$210,000.00 Price / Sales502.97 Cash FlowN/A Price / Cash FlowN/A Book Value$0.85 per share Price / Book2.67Profitability EPS (Most Recent Fiscal Year)($0.47) Net Income$-21,430,000.00 Net MarginsN/A Return on Equity-49.42% Return on Assets-46.19%Miscellaneous Employees11 Outstanding Shares46,530,000Market Cap$105.62 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:MRKR Rates by TradingView Receive MRKR News and Ratings via Email Sign-up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter. TapImmune (NASDAQ:MRKR) Frequently Asked Questions How has TapImmune's stock been impacted by COVID-19 (Coronavirus)? TapImmune's stock was trading at $1.98 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MRKR shares have increased by 14.6% and is now trading at $2.27. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of TapImmune? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TapImmune in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for TapImmune. When is TapImmune's next earnings date? TapImmune is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for TapImmune. How were TapImmune's earnings last quarter? TapImmune Inc. (NASDAQ:MRKR) announced its quarterly earnings data on Monday, May, 11th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.03. View TapImmune's earnings history. What price target have analysts set for MRKR? 5 Wall Street analysts have issued 12 month price targets for TapImmune's stock. Their forecasts range from $2.50 to $16.00. On average, they expect TapImmune's share price to reach $8.90 in the next year. This suggests a possible upside of 292.1% from the stock's current price. View analysts' price targets for TapImmune. Has TapImmune been receiving favorable news coverage? Media stories about MRKR stock have been trending positive on Sunday, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. TapImmune earned a news impact score of 2.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news aboutTapImmune. Who are some of TapImmune's key competitors? Some companies that are related to TapImmune include Calithera Biosciences (CALA), CytomX Therapeutics (CTMX), XBiotech (XBIT), Avedro (AVDR), Puma Biotechnology (PBYI), Albireo Pharma (ALBO), Seres Therapeutics (MCRB), Merus (MRUS), Aeglea Bio Therapeutics (AGLE), Axovant Sciences (AXON), MEI Pharma (MEIP), ANI Pharmaceuticals (ANIP), Ocular Therapeutix (OCUL), Progenics Pharmaceuticals (PGNX) and Wave Life Sciences (WVE). View all competitors. What other stocks do shareholders of TapImmune own? Based on aggregate information from My MarketBeat watchlists, some companies that other TapImmune investors own include SCYNEXIS (SCYX), Viking Therapeutics (VKTX), Ionis Pharmaceuticals (IONS), Amarin (AMRN), Alibaba Group (BABA), Flexion Therapeutics (FLXN), Outlook Therapeutics (OTLK), AzurRx BioPharma (AZRX), Genocea Biosciences (GNCA) and InVitae (NVTA). Who are TapImmune's key executives? TapImmune's management team includes the following people: Mr. Peter L. Hoang MBA, Pres, CEO & Director (Age 47)Mr. Anthony H. Kim, Chief Financial Officer (Age 43)Mr. Michael J. Loiacono, Chief Accounting Officer, Treasurer & Sec. (Age 53)Dr. Ann M. Leen, Chief Scientific OfficerMs. Elizabeth Donnelly, Director of Admin. What is TapImmune's stock symbol? TapImmune trades on the NASDAQ under the ticker symbol "MRKR." How do I buy shares of TapImmune? Shares of MRKR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is TapImmune's stock price today? One share of MRKR stock can currently be purchased for approximately $2.27. How big of a company is TapImmune? TapImmune has a market capitalization of $105.62 million and generates $210,000.00 in revenue each year. The company earns $-21,430,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. TapImmune employs 11 workers across the globe. What is TapImmune's official website? The official website for TapImmune is www.markertherapeutics.com. How can I contact TapImmune? TapImmune's mailing address is 3200 Southwest Freeway Suite 2240, Houston TX, 77027. The company can be reached via phone at 713-400-6400 or via email at [email protected] This page was last updated on 5/31/2020 by MarketBeat.com Staff
